Cochrane · systematic review · CD011419
Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain
Hamilton, TW, Athanassoglou, V, Mellon, S, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 0 · 0%Very low 7 · 50%Low 3 · 21.4%Moderate 2 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: liposomal bupivacaine vs placebo
Population: aged 18 years and older undergoing elective surgery at any surgical site
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cumulative pain score from the end of operation (0 hours) to 72 hours (NRS 0 to 10) Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 1 study · 189 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 2 studies · 382 participants | Low Downgraded: risk of bias, imprecision |
Mean pain score at 12, 24, 48, 72 and 96 hours following surgery (NRS 0 to 10) Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | NR | No studies |
Time to first postoperative opioid dose over initial 72 hours Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 2 studies · 382 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Total postoperative opioid consumption over first 72 hours Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 1 study · 189 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Percentage of participants not requiring postoperative opioids over initial 72 hours Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 2 studies · 382 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Incidence of adverse events within 30 days of surgery Summary of findings: liposomal bupivacaine vs placebo | no estimate extracted | 2 studies · 382 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride
Population: aged 18 years and older undergoing elective surgery at any surgical site
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cumulative pain score from the end of operation (0 hours) to 72 hours (NRS 0 to 10) Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 2 studies · 379 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 3 studies · 583 participants | Moderate Downgraded: risk of bias, imprecision |
Mean pain score at 12, 24, 48, 72 and 96 hours following surgery (NRS 0 to 10) Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 1 study · 134 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Time to first postoperative opioid dose over initial 72 hours Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | NR | No studies |
Total postoperative opioid consumption over first 72 hours Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 1 study · 134 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Percentage of participants not requiring postoperative opioids over initial 72 hours Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 1 study · 134 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Incidence of adverse events within 30 days of surgery Summary of findings: liposomal bupivacaine vs bupivacaine hydrochloride | no estimate extracted | 3 studies · 583 participants | Moderate Downgraded: risk of bias, imprecision |